Probiotics and Antimicrobial Proteins

, Volume 11, Issue 4, pp 1124–1131 | Cite as

Validated Postbiotic Screening Confirms Presence of Physiologically-Active Metabolites, Such as Short-Chain Fatty Acids, Amino Acids and Vitamins in Hylak® Forte

  • Satish Patil
  • Sarvesh Sawant
  • Karlheinz Hauff
  • Gabriele HamppEmail author


Hylak® forte is a postbiotic that inhibits the growth of pathogenic bacteria by reducing intestinal pH. It is assumed the potential presence of short-chain fatty acids (SCFAs) in Hylak® forte may contribute to this effect. In this current study, we analysed the composition of Hylak® forte, using a validated gas chromatography assay test method, to ascertain whether SCFAs are present in this postbiotic treatment. Hylak® forte was screened for C1 to C10 SCFAs by a gas chromatographic assay. In this assay, SCFAs were analysed as for their volatile ethyl ester derivatives in a 3.0 mL Hylak® forte sample. An additional screening procedure was conducted for the presence of vitamins and simple sugars. The gas chromatographic method for determining SCFAs was validated according to the requirements of ICH guideline Q2 (R1). Formic and acetic acids were identified in Hylak® forte at 27.92 ppm (90% confidence interval (CI), 26.90–28.94) and 306.17 ppm (90% CI, 277.11–335.22), respectively. Additional compounds were quantified in the solution, including vitamin B1 (0.029 mg/100 g), monosaccharides and disaccharides (2.767 g/100 g), as well as glutamic acid and glutamine (0.047 g/100 g). This study has identified formic acid in a range of 39.33 (90% CI, 36.50–42.17)–48.33 (90% CI, 45.91–50.76) ppm and acetic acid dropping down to 312.33 (90% CI, 295.32–329.35) from initial 415.67 ppm (90% CI, 385.93–445.41) in commercial Hylak® forte samples under forced degradation conditions. In addition, a range of other compounds in Hylak® forte was identified, including riboflavin and glutamine. Further studies are necessary to establish whether these compounds translate into tangible therapeutic effects.


Hylak forte SCFA Postbiotics Metabiotics Vitamins Gastrointestinal tract 



This study was sponsored by Ratiopharm GmbH, which is an affiliate of Teva Pharmaceutical Industries Ltd. Medical writing support was provided by Matthew Gunther, PhD, of Zoetic Science, an Ashfield company, part of UDG Healthcare plc, and was funded by Ratiopharm GmbH (Ulm, Germany).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kamada N, Chen GY, Inohara N, Núñez G (2013) Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 14:685–690. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Neis EPJG, Dejong CHC, Rensen SS (2015) The role of microbial amino acid metabolism in host metabolism. Nutrients 7:2930–2946. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Thursby E, Juge N (2017) Introduction to the human gut microbiota. Biochem J 474:1823–1836. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Conlon MA, Bird AR (2014) The impact of diet and lifestyle on gut microbiota and human health. Nutrients 7:17–44. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC (2011) Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 141:769–776. CrossRefPubMedGoogle Scholar
  6. 6.
    Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, Blanchard C, Junt T, Nicod LP, Harris NL, Marsland BJ (2014) Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 20:159–166. CrossRefGoogle Scholar
  7. 7.
    Vieira AT, Fukumori C, Ferreira CM (2016) New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases. Clin Transl Immunol 5:e87. CrossRefGoogle Scholar
  8. 8.
    Adams CA (2010) The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev 23:37–46. CrossRefPubMedGoogle Scholar
  9. 9.
    Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A (2012) Probiotic mechanisms of action. Ann Nutr Metab 61:160–174. CrossRefPubMedGoogle Scholar
  10. 10.
    Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580–591. CrossRefPubMedGoogle Scholar
  11. 11.
    Tsilingiri K, Rescigno M (2013) Postbiotics: what else? Benefic Microbes 4:101–107. CrossRefGoogle Scholar
  12. 12.
  13. 13.
    Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de los Reyes-Gavilán CG, Salazar N (2016) Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol 7:185. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Macfarlane GT, Macfarlane S (2012) Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int 95:50–60. CrossRefPubMedGoogle Scholar
  15. 15.
    (2005) ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology Q2(R1). Accessed 2016
  16. 16.
    Metcalfe LD, Schmitz AA (1961) The rapid preparation of fatty acid esters for gas chromatographic analysis. Anal Chem 33:363–364. CrossRefGoogle Scholar
  17. 17.
    Shenderov BA (2013) Metabiotics: novel idea or natural development of probiotic conception. Microb Ecol Health Dis 24:20399. CrossRefGoogle Scholar
  18. 18.
    Belousova EF, Nikitine YV, Mishurovskaya NC, Zlatkina AR (2005) Possibilities of microbial metabolite preparations for intestinal microbiota restoration. Cons Medicum 7:9–13Google Scholar
  19. 19.
    Hiller E, Schach H (1955) Clinical and experimental experiences on the possibility of the influence of yoghurt metabolites on pathological conditions of intestinal flora. Arzneimittelforschung 5:592–599PubMedGoogle Scholar
  20. 20.
    Konig H, Manz W, Singer U (1991) Influence on intestinal bacteria. Basic principles of treatment using bacterial metabolic products. Der Kassenarzt 18:52–61Google Scholar
  21. 21.
    Krieger D, Vanek E, Manz W, Elsasser R (1991) Influence of bacterial metabolic products on the fecal flora of healthy volunteers and on added pathogenic bacteria. Nb Med 4:169–172Google Scholar
  22. 22.
    den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM (2013) The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 54:2325–2340. CrossRefGoogle Scholar
  23. 23.
    Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H, Hattori M, Ohno H (2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469:543–547. CrossRefPubMedGoogle Scholar
  24. 24.
    Cummings JH (1981) Short chain fatty acids in the human colon. Gut 22:763–779. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Topping DL, Clifton PM (2001) Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 81:1031–1064. CrossRefPubMedGoogle Scholar
  26. 26.
    Morrison DJ, Preston T (2016) Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7:189–200. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Miller TL, Wolin MJ (1996) Pathways of acetate, propionate, and butyrate formation by the human fecal microbial flora. Appl Environ Microbiol 62:1589–1592PubMedPubMedCentralGoogle Scholar
  28. 28.
    Flint HJ, Duncan SH, Scott KP, Louis P (2015) Links between diet, gut microbiota composition and gut metabolism. Proc Nutr Soc 74:13–22. CrossRefPubMedGoogle Scholar
  29. 29.
    Macfarlane S, Macfarlane GT (2003) Regulation of short-chain fatty acid production. Proc Nutr Soc 62:67–72. CrossRefPubMedGoogle Scholar
  30. 30.
    Louis P, Hold GL, Flint HJ (2014) The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12:661–672. CrossRefPubMedGoogle Scholar
  31. 31.
    Pomare EW, Branch WJ, Cummings JH (1985) Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J Clin Invest 75:1448–1454. CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Pessione E (2012) Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows. Front Cell Infect Microbiol 2:86. CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Elshaghabee FMF, Bockelmann W, Meske D, de Vrese M, Walte HG, Schrezenmeir J, Heller KJ (2016) Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions. Front Microbiol 7:47. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Enjalbert B, Millard P, Dinclaux M, Portais JC, Létisse F (2017) Acetate fluxes in Escherichia coli are determined by the thermodynamic control of the Pta-AckA pathway. Sci Rep 7:42135. CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Torino MI, Mozzi F, Font de Valdez G (2005) Exopolysaccharide biosynthesis by Lactobacillus helveticus ATCC 15807. Appl Microbiol Biotechnol 68:259–265. CrossRefPubMedGoogle Scholar
  36. 36.
    Tedelind S, Westberg F, Kjerrulf M, Vidal A (2007) Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 13:2826–2832. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM, Wise A, Dowell SJ (2003) The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278:11312–11319. CrossRefPubMedGoogle Scholar
  38. 38.
    Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, di Yu, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:1282–1286. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hill MJ (1997) Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 6(Suppl 1):S43–S45. CrossRefPubMedGoogle Scholar
  40. 40.
    Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, Tuohy K (2018) Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr 57:1–24. CrossRefPubMedGoogle Scholar
  41. 41.
    Magnúsdóttir S, Ravcheev D, de Crécy-Lagard V, Thiele I (2015) Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. Front Genet 6:148. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Said HM, Ortiz A, Moyer MP, Yanagawa N (2000) Riboflavin uptake by human-derived colonic epithelial NCM460 cells. Am J Phys Cell Phys 278:C270–C276. CrossRefGoogle Scholar
  43. 43.
    Shin R, Suzuki M, Morishita Y (2002) Influence of intestinal anaerobes and organic acids on the growth of enterohaemorrhagic Escherichia coli O157:H7. J Med Microbiol 51:201–206. CrossRefPubMedGoogle Scholar
  44. 44.
    Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME (2014) Expert consensus document. The international scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506–514. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Satish Patil
    • 1
  • Sarvesh Sawant
    • 1
  • Karlheinz Hauff
    • 2
  • Gabriele Hampp
    • 2
    Email author
  1. 1.Teva Pharmaceutical IndustriesVernaIndia
  2. 2.Ratiopharm GmbHUlmGermany

Personalised recommendations